MA32751B1 - Antagoniste sélectif du récepteur opioïde kappa - Google Patents
Antagoniste sélectif du récepteur opioïde kappaInfo
- Publication number
- MA32751B1 MA32751B1 MA33041A MA33041A MA32751B1 MA 32751 B1 MA32751 B1 MA 32751B1 MA 33041 A MA33041 A MA 33041A MA 33041 A MA33041 A MA 33041A MA 32751 B1 MA32751 B1 MA 32751B1
- Authority
- MA
- Morocco
- Prior art keywords
- opioid receptor
- selective antagonist
- receptor kappa
- kappa
- selective
- Prior art date
Links
- 102000003840 Opioid Receptors Human genes 0.000 title 1
- 108090000137 Opioid Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 239000002618 kappa opiate receptor antagonist Substances 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08380012 | 2008-01-22 | ||
| US3912108P | 2008-03-25 | 2008-03-25 | |
| PCT/US2009/030811 WO2009094260A1 (en) | 2008-01-22 | 2009-01-13 | Kappa selective opioid receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA32751B1 true MA32751B1 (fr) | 2011-11-01 |
Family
ID=40876972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA33041A MA32751B1 (fr) | 2008-01-22 | 2010-07-19 | Antagoniste sélectif du récepteur opioïde kappa |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US7709522B2 (OSRAM) |
| EP (1) | EP2252581B1 (OSRAM) |
| JP (1) | JP5345637B2 (OSRAM) |
| KR (1) | KR101172170B1 (OSRAM) |
| CN (1) | CN101925576B (OSRAM) |
| AR (1) | AR070158A1 (OSRAM) |
| AU (1) | AU2009206653B2 (OSRAM) |
| BR (1) | BRPI0907382B8 (OSRAM) |
| CA (1) | CA2713025C (OSRAM) |
| CO (1) | CO6290644A2 (OSRAM) |
| CY (1) | CY1113071T1 (OSRAM) |
| DK (1) | DK2252581T3 (OSRAM) |
| DO (1) | DOP2010000222A (OSRAM) |
| EA (1) | EA017484B1 (OSRAM) |
| EC (1) | ECSP10010365A (OSRAM) |
| ES (1) | ES2388708T3 (OSRAM) |
| HR (1) | HRP20120558T1 (OSRAM) |
| IL (1) | IL206038A (OSRAM) |
| JO (1) | JO2797B1 (OSRAM) |
| MA (1) | MA32751B1 (OSRAM) |
| MX (1) | MX2010007849A (OSRAM) |
| MY (1) | MY163014A (OSRAM) |
| NZ (1) | NZ586225A (OSRAM) |
| PE (1) | PE20091317A1 (OSRAM) |
| PL (1) | PL2252581T3 (OSRAM) |
| PT (1) | PT2252581E (OSRAM) |
| SI (1) | SI2252581T1 (OSRAM) |
| TN (1) | TN2010000306A1 (OSRAM) |
| TW (1) | TWI422369B (OSRAM) |
| UA (1) | UA100715C2 (OSRAM) |
| WO (1) | WO2009094260A1 (OSRAM) |
| ZA (1) | ZA201003908B (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201070876A1 (ru) * | 2008-01-22 | 2011-04-29 | Такеда Фармасьютикал Компани Лимитед | Трициклические соединения, обладающие антагонистической активностью по отношению к кортикотропин-высвобождающему фактору, и содержащие их фармацевтические композиции |
| JO2797B1 (en) * | 2008-01-22 | 2014-03-15 | ايلي ليلي اند كومباني | Selective opioid receptor antagonist kappa |
| US9345703B2 (en) | 2011-09-15 | 2016-05-24 | University Of Kansas | Kappa opioid receptor effectors and uses thereof |
| WO2013042054A1 (en) | 2011-09-19 | 2013-03-28 | Carmel - Haifa University Economic Corporation Ltd. | Buprenorphine for the treatment of acute suicidality |
| JP6061948B2 (ja) | 2011-12-09 | 2017-01-18 | リサーチ トライアングル インスティテュート | κオピオイド受容体アンタゴニストとしての１−置換４−アリールピペラジン |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| US9283196B1 (en) | 2013-01-30 | 2016-03-15 | MediSynergics, LLC | Cycloalkyl-diamines for CNS disorders |
| JP2016519161A (ja) * | 2013-05-24 | 2016-06-30 | アルカームス ファーマ アイルランド リミテッド | モルファン及びモルフィナン類似物及び使用の方法 |
| US10316021B2 (en) | 2016-11-28 | 2019-06-11 | Pfizer Inc. | Heteroarylphenoxy benzamide kappa opioid ligands |
| CN110914262B (zh) | 2017-03-17 | 2024-04-05 | 斯克里普斯研究所 | κ阿片受体拮抗剂以及与其相关的产品和方法 |
| JP6480616B1 (ja) | 2018-02-08 | 2019-03-13 | 有限会社 ディオン光学技研 | 照準スコープ |
| US11266627B1 (en) | 2021-05-04 | 2022-03-08 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| CN114195693A (zh) * | 2020-09-17 | 2022-03-18 | 广东东阳光药业有限公司 | 一种酰胺化合物的晶型及其制备方法 |
| CN114591211B (zh) * | 2020-12-04 | 2025-10-21 | 广东东阳光药业股份有限公司 | 一种酰胺化合物的共晶及其制备方法 |
| WO2022234457A1 (en) | 2021-05-04 | 2022-11-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| US12161622B2 (en) | 2021-05-04 | 2024-12-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| IL314176A (en) * | 2022-01-10 | 2024-09-01 | Janssen Pharmaceuticals Inc | Compositions and methods for treating depression |
| US20250221960A1 (en) * | 2022-01-10 | 2025-07-10 | Janssen Pharmaceuticals, Inc. | Compositions and methods for the treatment of depression |
| PE20242109A1 (es) * | 2022-03-07 | 2024-10-28 | Janssen Pharmaceuticals Inc | Formas puras de aticaprant cristalino |
| CA3254546A1 (en) * | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | COMPOSITIONS CONTAINING ATICAPRANT |
| WO2023170550A1 (en) | 2022-03-07 | 2023-09-14 | Janssen Pharmaceuticals, Inc. | Polymorph forms of aticaprant for use in treating major depressive disorder |
| JP7176142B1 (ja) | 2022-03-09 | 2022-11-21 | 直迪 清瀬 | 各アルコール飲用者において飲用し得るアルコール飲料の種類に対応する飲用量の上限値に関する情報を提供するシステム |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5457208A (en) | 1993-06-21 | 1995-10-10 | Regents Of The University Of Minnesota | Kappa opioid receptor antagonists |
| CN1164590C (zh) * | 1999-05-12 | 2004-09-01 | 弗·哈夫曼-拉罗切有限公司 | 咪唑二氮杂�衍生物 |
| AU2001292164A1 (en) * | 2000-10-05 | 2002-04-15 | Hanns Mohler | Selective anxiolytic therapeutic agents |
| EP1353665A4 (en) | 2000-12-21 | 2004-05-06 | Mclean Hospital Corp | Treatment of depression |
| US6974824B2 (en) | 2001-01-08 | 2005-12-13 | Research Triangle Institute | Kappa opioid receptor ligands |
| KR100865410B1 (ko) * | 2002-03-28 | 2008-10-24 | 위시스 테크놀로지 파운데이션, 인크. | 진정 및 운동실조 효과가 감소된 항불안제 |
| ES2305491T3 (es) | 2002-09-19 | 2008-11-01 | Eli Lilly And Company | Eteres de diarilo como antagonistas de receptores de opioides. |
| DE602004016127D1 (de) | 2003-03-07 | 2008-10-09 | Lilly Co Eli | Antagonisten der opioidrezeptoren |
| ATE377589T1 (de) | 2003-03-07 | 2007-11-15 | Lilly Co Eli | 6-substituierte nikotinamidderivate als opioidrezeptorantagonisten |
| CA2549009A1 (en) | 2003-12-12 | 2005-07-07 | Eli Lilly And Company | Opioid receptor antagonists |
| EP1699783B1 (en) | 2003-12-22 | 2012-07-25 | Eli Lilly And Company | Opioid receptor antagonists |
| WO2005090286A1 (en) | 2004-03-12 | 2005-09-29 | Eli Lilly And Company | Opioid receptor antagonists |
| CA2559207A1 (en) | 2004-03-12 | 2005-09-29 | The Mclean Hospital Corporation | Salvinorin derivatives and uses thereof |
| EP1730140B1 (en) | 2004-03-12 | 2008-06-25 | Eli Lilly And Company | Opioid receptor antagonists |
| CA2557794A1 (en) | 2004-03-15 | 2005-10-06 | Eli Lilly And Company | Opioid receptor antagonists |
| CA2558030A1 (en) | 2004-03-15 | 2005-09-29 | Eli Lilly And Company | 4- (5- (aminomethyl) -indole-1-ylmethyl) -benzamide derivatives and related compounds as opioid receptor antagonists for the treatment of obesity |
| WO2007067714A2 (en) | 2005-12-08 | 2007-06-14 | The Mclean Hospital Corporation | Treatment of sequelae of psychiatric disorders |
| HRP20100113T1 (hr) | 2006-04-04 | 2010-04-30 | Emodys Gmbh | Upotreba pripravaka koji sadrže antagonist kapa-opioidnog receptora, namijenjenih liječenju disocijativnih poremećaja |
| WO2008021851A2 (en) | 2006-08-09 | 2008-02-21 | Smithkline Beecham Corporation | Novel compounds as antagonists or inverse agonists for opioid receptors |
| US8633175B2 (en) | 2006-08-09 | 2014-01-21 | Glaxosmithkline Llc | Compounds as antagonists or inverse agonists at opioid receptors |
| CA2662766C (en) | 2006-09-08 | 2011-08-09 | Pfizer Products Inc. | Diaryl ether derivatives and uses thereof |
| JO2797B1 (en) * | 2008-01-22 | 2014-03-15 | ايلي ليلي اند كومباني | Selective opioid receptor antagonist kappa |
-
2009
- 2009-01-13 JO JO200915A patent/JO2797B1/en active
- 2009-01-13 EP EP09703808A patent/EP2252581B1/en active Active
- 2009-01-13 PE PE2009000036A patent/PE20091317A1/es active IP Right Grant
- 2009-01-13 US US12/352,869 patent/US7709522B2/en active Active
- 2009-01-13 PL PL09703808T patent/PL2252581T3/pl unknown
- 2009-01-13 WO PCT/US2009/030811 patent/WO2009094260A1/en not_active Ceased
- 2009-01-13 BR BRPI0907382A patent/BRPI0907382B8/pt active IP Right Grant
- 2009-01-13 JP JP2010543182A patent/JP5345637B2/ja active Active
- 2009-01-13 ES ES09703808T patent/ES2388708T3/es active Active
- 2009-01-13 MX MX2010007849A patent/MX2010007849A/es active IP Right Grant
- 2009-01-13 NZ NZ586225A patent/NZ586225A/en unknown
- 2009-01-13 KR KR1020107016401A patent/KR101172170B1/ko active Active
- 2009-01-13 AU AU2009206653A patent/AU2009206653B2/en active Active
- 2009-01-13 TW TW098101083A patent/TWI422369B/zh active
- 2009-01-13 EA EA201070877A patent/EA017484B1/ru not_active IP Right Cessation
- 2009-01-13 CN CN2009801026504A patent/CN101925576B/zh active Active
- 2009-01-13 SI SI200930326T patent/SI2252581T1/sl unknown
- 2009-01-13 UA UAA201008931A patent/UA100715C2/ru unknown
- 2009-01-13 HR HRP20120558AT patent/HRP20120558T1/hr unknown
- 2009-01-13 AR ARP090100098A patent/AR070158A1/es not_active Application Discontinuation
- 2009-01-13 PT PT09703808T patent/PT2252581E/pt unknown
- 2009-01-13 CA CA2713025A patent/CA2713025C/en active Active
- 2009-01-13 MY MYPI2010003437A patent/MY163014A/en unknown
- 2009-01-13 DK DK09703808.7T patent/DK2252581T3/da active
-
2010
- 2010-04-09 US US12/757,451 patent/US8173695B2/en active Active
- 2010-05-27 IL IL206038A patent/IL206038A/en active IP Right Grant
- 2010-06-01 ZA ZA2010/03908A patent/ZA201003908B/en unknown
- 2010-06-30 TN TN2010000306A patent/TN2010000306A1/fr unknown
- 2010-07-19 MA MA33041A patent/MA32751B1/fr unknown
- 2010-07-20 DO DO2010000222A patent/DOP2010000222A/es unknown
- 2010-07-22 EC EC2010010365A patent/ECSP10010365A/es unknown
- 2010-08-12 CO CO10099271A patent/CO6290644A2/es active IP Right Grant
-
2012
- 2012-08-24 CY CY20121100765T patent/CY1113071T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA32751B1 (fr) | Antagoniste sélectif du récepteur opioïde kappa | |
| EA200900152A1 (ru) | Ингибиторы пирролотриазинкиназы | |
| MA32898B1 (fr) | Modulateurs allosteriques positifs du recepteur m1 d'arylmethylbenzoquinazolinone | |
| UA112055C2 (uk) | Солі 4-[2-[[5-метил-1-(2-нафталініл)-1h-піразол-3-іл]оксі]етил]морфоліну | |
| HRP20090235A2 (hr) | Karbonilirani (aza) cikloheksani kao ligandi dopaminskog receptora d<sub>3</sub> | |
| MA31084B1 (fr) | Derives de piperidine agonistes de gpcr | |
| UA102251C2 (ru) | Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера | |
| MA35285B1 (fr) | Indazoles | |
| BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
| MA33053B1 (fr) | Inhibiteurs de la poly(adp-ribose) polymerase (parp) | |
| MA31593B1 (fr) | Derives de 2-aza-bicyclo[3.3.0]octane | |
| MA31158B1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes | |
| BRPI0714315B8 (pt) | arilamidas substituídas com tetrazol, seu uso e composição farmacêutica que as compreende | |
| MA31699B1 (fr) | Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3 | |
| DE602006018301D1 (de) | Histamin-3-rezeptorantagonisten | |
| DE602007006961D1 (de) | Cgrp-rezeptorantagonisten | |
| EA200970341A1 (ru) | Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов | |
| DK2081572T3 (da) | Benzimidazol-cannabinoid-agonister med en substitueret heterocyklisk gruppe | |
| EA200970835A1 (ru) | Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета | |
| MA33721B1 (fr) | Derives sulfonamides heterocycliques utilises comme inhibiteurs de mek | |
| ATE534632T1 (de) | Thiazole, imidazole und pyrazole als proteinkinasehemmer | |
| MX346186B (es) | Inhibidores de proteina cinasas. | |
| MA31700B1 (fr) | Derives d'azacyclylisoquinolinone et -isoindolinone servant d'antagonistes du recepteur d'histamine-3 | |
| MA30703B1 (fr) | Dérivés de 5,6-bisaryl-2-pyridine-carboxamide, leur préparation et leur application en thérapeutique comme antagonistes des recepteurs a l'urotensine ii. | |
| NO20091052L (no) | Diaryleterderivater og anvendelser derav |